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method of intervention, complications, and recurrence.
RESULTS Of the 112 patients who went to the lab, we analyzed data
encompassing 216 veins with 39 veins not intervened upon secondary
to complete occlusion or lack of substantial PV-LA pressure gradient.
After an initial 94% procedural success rate, there were 76 PVS re-
currences (44%) over a median follow up time of 4.6 years. We found
those who experienced PVS recurrence had signiﬁcantly higher post-
procedure PV/LA gradients (3.84.9 mmHg vs 1.71.8 mmHg,
p¼0.001) compared to those who avoided recurrence. Patients who
underwent initial stenting compared to balloon dilatation had a 44%
reduction in recurrence compared to those who underwent balloon
dilatation only (RR¼0.56, 95% CI 0.41 to 0.75, p<0.0001, Figure 1). We
also note signiﬁcantly higher balloon atmosphere inﬂations among
patients who did not recur (9.14.0 atm vs 7.32.3 atm, p¼0.007) with
no difference in pre-procedural lesion characteristics or stent/balloon
size.
CONCLUSIONS These results demonstrate PVS recurrence is com-
mon, and is more likely to occur over a lengthy follow up in those
who initially underwent balloon dilatation compared to stenting.
Furthermore, difﬁcult lesions where higher balloon insufﬂation
cannot be achieved resulting in higher post-procedure PV/LA gradi-
ents are more likely to result in recurrence. Thus, PVS should be
initially treated with stenting to avoid further sequelae of PVI such as
recurrent PVS.
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BACKGROUND Optimal therapeutic strategies for patients with
atrial septal defect (ASD) complicated with severe pulmonary arte-
rial hypertension (PAH) is controversial. Combination of recent
advanced PAH speciﬁc medication and transcatheter ASD closure
may contribute the improvement of therapeutic outcome in these
difﬁcult patients population. Our purpose was to evaluate the efﬁ-
cacy of PAH-speciﬁc medications combined with transcatheter
closure.
METHODS Between January 2006 and December 2013, 780 patients
with ASD were performed transcatheter closure, and 48 of 780 pa-
tients (6.2%) complicated with PAH (mean pulmonary artery
pressure  25 mm Hg). Following patients were excluded from thisstudy because of pulmonary hypertension related to lung diseases
(n¼8), left ventricular systolic dysfunction (n¼1) and pulmonary em-
bolism (n¼1). Among 38 patients with PAH associated with ASD, 3
patients excluded because the defects was too large for device
deployment. A total of 35 patients underwent successful procedures
and were included in this study. Among of these, 8 patients with se-
vere PAH required of PAH-speciﬁc medication (PAH speciﬁc group)
and compared to 40 patients who did not required of PAH-speciﬁc
medication (non PAH-speciﬁc group) were studied. PAH-speciﬁc
medications included an endothelin receptor antagonist (bosentan;
n ¼ 4), a phosphodiesterase type-5 inhibitor (sildenaﬁl; n ¼ 4), an oral
prostanoid (beraprost; n ¼ 1), and an intravenous prostanoid (epo-
prostenol; n ¼ 2).
RESULTS After the induction of PAH speciﬁc medication (mean 6.6
months), transcatheter ASD closure was successfully performed in all
without hemodynamic intolerances. Mean device size was 26  7 mm
and the mean ﬂuoroscopic time was 15  8 min. Multiple devices were
required in 2 patients. No hemodynamic compromise occurred in any
of the patients during or after the procedure. Improvement of systolic
PAP was signiﬁcantly greater in PAH-speciﬁc group compared to non
PAH-speciﬁc group (median, 49; range, 26 to 105 mm Hg vs. median,
14; range 4 to 77 mm Hg, respectively; p ¼ 0.0014). Among 29 patients
with symptomatic heart failure, improved heart failure symptoms was
observed in 21 (72%) patients with no exacerbation of heart failure.
Compared with the initial evaluation, BNP levels signiﬁcantly
improved at follow-up at follow-up period (p ¼ 0.0017). During the
mean observational period of 45  25 months, one patient required
hospital admission due to the progression of sick sinus syndrome. No
other adverse events including hospitalization of exacerbation of PAH
were observed.
CONCLUSIONS Even in patients with severe PAH, who initially did
not fulﬁll the indication of transcatheter ASD closure, the recent PAH
speciﬁc medication can contribute the signiﬁcant improvement of
hemodynamic condition. This treat and repair strategies may expand
of therapeutic indication for transcatheter ASD closure in patients
with severe PAH.
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BACKGROUND Transcatheter closure of large post-tricuspid shunts
in patients with severe pulmonary arterial hypertension (PAH) re-
mains a challenging clinical problem. In neonates and infants it is
most often reversible, but in older patients the resolution of PAH
is variable depending on the reversibility of pulmonary vascular
resistance. The current study was done to assess the safety and ef-
ﬁcacy of percutaneous device closure of large post tricuspid
shunts in pediatric patients with severe PAH at short and mid term
follow up.
METHODS A total of 42 pediatric patients underwent transcatheter
closure of large post tricuspid shunts with severe PAH. All subjects
underwent clinical examination, electrocardiography, chest x-rays
and echocardiography before discharge and at 1, 6 and 12 months after
the procedure and yearly thereafter for 5 years.
RESULTS Type of defect was ventricular septal defect in 8 patients
(19%), patent ductus arteriosus in 27 patients (64%), aorto-pulmonary
window in 5 patients (12%) and coronary cameral ﬁstula in two pa-
tients (5%). Cardi-O-Fix VSD occluder was the most commonly used
device (45%), Cardi-O-Fix PDA occluder (21%) and Amplatzer duct
occlude in 17% patients. Pre-procedural pulmonary artery systolic
pressure decreased signiﬁcantly from mean 81.12 mmHg to mean
43.17 mmHg post procedure over a mean follow-up of 18.5 months. No
residual shunt was found in 38 (90.47%) patients. Only two major
complications viz; severe aortic obstruction and symptomatic com-
plete heart block were noticed.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B13CONCLUSIONS Our study showed that the transcatheter closure
of large post tricuspid shunts in pediatric patients with severe
PAH was safe, feasible and efﬁcacious alternative to conventional
surgery.
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BACKGROUND Population studies have identiﬁed a correlation be-
tween migraine and patent foramen ovale (PFO), and observational
studies have reported that PFO closure results in improvement in
migraine in some patients. The PREMIUM Trial was a randomized,
sham-controlled, double blind study of percutaneous closure of PFO
with the AMPLATZER PFO Occluder (St. Jude Medical, Inc.) as a
treatment for migraine with or without aura.
METHODS 230 subjects with medically intractable migraine with or
without aura, who also had a patent foramen ovale (PFO), were ran-
domized to either a sham procedure plus medical therapy (107) or
percutaneous closure of the PFO plus medical therapy (123). Inclusion
criteria for randomization included 6 - 14 days of migraine per month
as assessed by a headache specialist, and failure (either lack of efﬁcacy
or intolerance) of 3 preventive medications and a signiﬁcant right to
left cardiac shunt (Spencer grade 4-5) determined by a screening
TransCranial Doppler (TCD) intravenous agitated saline study. Sub-
jects were randomized on the catheterization table after proof of a
PFO was established, to device closure versus a sham control. Subjects
and headache specialists were blinded to the randomization alloca-
tion. The primary efﬁcacy endpoint was the responder rate percent
deﬁned as a 50% reduction in migraine attacks per month based on
the diary during months 10-12 post randomization. Subjects in the
control arm could receive the device after the 1-year blind was over.
The primary safety endpoint was the proportion of subjects who
experienced a device related serious adverse event through 1 year of
follow-up.
RESULTS There was no difference in the responder rate between the
device (38%) and the control groups (32%, p¼0.3). The device was
safe: there was 1/202 (0.5%) device related serious adverse event,
which was a transient episode of atrial ﬁbrillation. Secondary
endpoint analysis showed a signiﬁcant reduction in the total number
of headache days (3.4 vs 2.0 days, p¼0.03) in the device group. A
subset analysis revealed that subjects for whom the majority of
migraine attacks included aura had a particularly signiﬁcant reduction
in headache days (19/39, 49% responder rate vs 9/40, 23% responder
rate, p¼0.015). Complete remission of migraine occurred in 10.8% (8/
74) of the device group and 1.5% (1/68) of controls who had a diagnosis
of migraine with aura (p¼0.02).
CONCLUSIONS Device closure of PFO can be performed safely, but
did not result in a 50% or greater decrease in migraine attack fre-
quency compared with a sham procedure, but there was a signiﬁcant
decrease in the mean number of headache days. Subgroup analysis
suggests that individuals with aura occurring during the majority of
their attacks may respond more favorably to PFO closure, and that a
small but signiﬁcant percentage of migraine with aura patients may
experience complete remission of migraine.
CATEGORIES STRUCTURAL: Congenital and Other Structural Heart
Disease
KEYWORDS Clinical Trial, Migraine, Patent foramen ovaleTCT-31
Title: Immediate and One Year U.S. IDE Trial Results of the New GORE
CARDIOFORM Septal Occluder for Transcatheter Closure of Secundum
Atrial Septal Defects
Joseph Paolillo,1 D. Scott Lim,2 Phillip Moore,3 Tom Forbes4
1Sanger Heart & Vascular Institute, Charlotte, NC; 2University of
Virginia Health Systems, Charlottesville, VA; 3University of California
San Francisco, San Francisco, CA; 4Children’s Hospital of Michigan,
Detroit, United States
BACKGROUND The GORE CARDIOFORM Septal Occluder (studied as
GORE Septal Occluder) was recently FDA approved for the trans-
catheter treatment of ostium secundum atrial septal defects. It is a
low proﬁle double disc device composed of a nitinol 5-wire frame, and
covered with expanded polytetraﬂuoroethylene. We present the ﬁrst
data including both Pivotal and early Continued Access trial subjects
with one year follow-up.
METHODS Patients were enrolled from 17 Pivotal and Continued Ac-
cess U.S. sites in a prospective single arm trial. Follow-up was
immediately post-procedure, and at scheduled intervals through one
year. Endpoints included successful device placement, immediate
and late closure success, and serious adverse events, including
serious device-related events requiring reintervention.
RESULTS Between October, 2012 and January, 2014, 125 patients were
enrolled with a median age of 7.4 years (range 2.4-78.6). Defects
treated had a static diameter of 10.03.2mm (maximum 17mm), and
stop ﬂow stretched diameter of 12.23.2mm (range 5.7-17.5). Deﬁcient
retroaortic rim (< 5.0 mm) was present in 36.3%, multiple fenestra-
tions in 18.4%, and atrial septal aneurysm in 10.4%. A CARDIOFORM
Septal Occluder was successfully implanted in 92% of patients (115/
125), with a serious adverse event rate of 0.8% at one year. Immediate
closure success (0-2 mm residual shunt) was 98.3% and a 2.1-4 mm
residual defect was present in 1.7%. Clinical closure success, deﬁned
as normalization of right heart size, was 100%. There were no cases of
post-procedural embolization or reintervention.
CONCLUSIONS The GORE CARDIOFORM Septal Occluder provides a
new option for percutaneous closure of small and medium-sized
secundum atrial septal defects, with high technical implant success,
occlusion rate, and safety proﬁle.
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BACKGROUND Left ventricle (LV) remodeling after anterior wall
myocardial infarction (AWMI) leads to increased LV volumes,
myocardial stress, and ultimately heart failure (HF). Treatment op-
tions are limited for these high-risk HF patients. Aims: The primary
objective is to continue to assess the long term safety of the Car-
dioKinetix Parachute Implant System in the partitioning of the
left ventricle in patients with heart failure due to ischemic heart
disease.
METHODS One hundred patients with NYHA class II-IV HF secondary
to AWMI, with akinetic or dyskinetic wall motion abnormality, and LV
ejection fraction < 40%, were enrolled in Europe. The primary
endpoint was site-reported procedural and device related MACE in
real world use of the Parachute Implant through 5 years of clinical
follow-up. In this report, two year data will be analyzed. Secondary
endpoints included changes in LVESVi and LVEDVi.
RESULTS As of the last data cut in early 2015, an analysis which
included 73 of the 100 PARACHUTE III patients, had a two year pro-
cedure / device related MACE rate of 9.2%. Two year follow-up of the
full cohort of 100 patients will be available for the TCT conference in
October 2015.
CONCLUSIONS The analysis of the post market data conﬁrms the
safety and longer term efﬁcacy of the Parachute device in treating HF.
